BR112018076247A2 - anticorpos monoclonais quiméricos e humanizados para cd81 - Google Patents
anticorpos monoclonais quiméricos e humanizados para cd81Info
- Publication number
- BR112018076247A2 BR112018076247A2 BR112018076247-4A BR112018076247A BR112018076247A2 BR 112018076247 A2 BR112018076247 A2 BR 112018076247A2 BR 112018076247 A BR112018076247 A BR 112018076247A BR 112018076247 A2 BR112018076247 A2 BR 112018076247A2
- Authority
- BR
- Brazil
- Prior art keywords
- chimeric
- monoclonal antibodies
- humanized monoclonal
- sequences
- cdr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
os anticorpos monoclonais quiméricos ou humanizados anti-cd81 (aglomerado ou diferenciação 81) são fornecidos no presente. os anticorpos se ligam a cd81 humano e são uteis em vários métodos terapêuticos incluindo sem limitação a redução ou prevenção de metástase de tumor. são também fornecidos sequências de regiões variáveis de cadeia leve e cadeia pesada, assim como as sequências de regiões determinantes da complementariedade (cdr) associadas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662351054P | 2016-06-16 | 2016-06-16 | |
US62/351,054 | 2016-06-16 | ||
PCT/US2017/037533 WO2017218691A1 (en) | 2016-06-16 | 2017-06-14 | Humanized and chimeric monoclonal antibodies to cd81 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018076247A2 true BR112018076247A2 (pt) | 2019-03-26 |
Family
ID=60664252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018076247-4A BR112018076247A2 (pt) | 2016-06-16 | 2017-06-14 | anticorpos monoclonais quiméricos e humanizados para cd81 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10815306B2 (pt) |
EP (1) | EP3471762A4 (pt) |
JP (1) | JP2019517813A (pt) |
CN (1) | CN109414492A (pt) |
BR (1) | BR112018076247A2 (pt) |
CA (1) | CA3027942A1 (pt) |
MA (1) | MA45404A (pt) |
RU (1) | RU2019100102A (pt) |
WO (1) | WO2017218691A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230068783A1 (en) * | 2020-01-21 | 2023-03-02 | Tavotek Biotherapeutics (Hong Kong) Limited | Agents that interfere with il-1beta receptor signalling |
WO2024079192A1 (en) | 2022-10-12 | 2024-04-18 | Institut National de la Santé et de la Recherche Médicale | Cd81 as a biomarker and biotarget in t-cell malignancies |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
JP2008520186A (ja) | 2004-10-01 | 2008-06-19 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 哺乳類eag1イオンチャネルタンパク質に対する新規の抗体 |
EP1885396A2 (en) * | 2005-05-04 | 2008-02-13 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against cd55 and cd59 and uses thereof |
CA2607147C (en) * | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
US7858752B2 (en) | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
US8858949B2 (en) * | 2009-08-06 | 2014-10-14 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
WO2011156520A2 (en) * | 2010-06-09 | 2011-12-15 | Green Pacific Biologicals, Inc. | Compositions and methods for increasing oil production and secretion |
CN103249833B (zh) * | 2010-12-06 | 2016-06-29 | 大日本住友制药株式会社 | 人单克隆抗体 |
US8440797B2 (en) * | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
CN104245736B (zh) * | 2012-10-26 | 2016-12-21 | 和元生物技术(上海)股份有限公司 | 抗人死亡受体5胞外区的人源化单克隆抗体 |
-
2017
- 2017-06-14 EP EP17814033.1A patent/EP3471762A4/en not_active Withdrawn
- 2017-06-14 JP JP2018566226A patent/JP2019517813A/ja active Pending
- 2017-06-14 RU RU2019100102A patent/RU2019100102A/ru not_active Application Discontinuation
- 2017-06-14 US US16/308,113 patent/US10815306B2/en active Active
- 2017-06-14 WO PCT/US2017/037533 patent/WO2017218691A1/en unknown
- 2017-06-14 MA MA045404A patent/MA45404A/fr unknown
- 2017-06-14 BR BR112018076247-4A patent/BR112018076247A2/pt not_active Application Discontinuation
- 2017-06-14 CN CN201780040994.1A patent/CN109414492A/zh active Pending
- 2017-06-14 CA CA3027942A patent/CA3027942A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2019100102A (ru) | 2020-07-16 |
JP2019517813A (ja) | 2019-06-27 |
EP3471762A1 (en) | 2019-04-24 |
MA45404A (fr) | 2019-04-24 |
US20190177425A1 (en) | 2019-06-13 |
EP3471762A4 (en) | 2020-03-11 |
CN109414492A (zh) | 2019-03-01 |
WO2017218691A1 (en) | 2017-12-21 |
CA3027942A1 (en) | 2017-12-21 |
US10815306B2 (en) | 2020-10-27 |
RU2019100102A3 (pt) | 2020-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
PH12021550023A1 (en) | Humanized anti-tau antibodies | |
BR112018072986A2 (pt) | anticorpos anti-pd-1 e anti-lag3 para tratamento de câncer | |
PH12016501212B1 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
MX2018012757A (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
GEP20227438B (en) | Pd-1-binding molecules and methods of use thereof | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
NZ738979A (en) | Pd-1 antibodies | |
TN2016000046A1 (en) | Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof | |
PE20190737A1 (es) | Anticuerpos anti-cd27 | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
EA201690447A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ | |
EA201890175A1 (ru) | Антитела к cd40 | |
MD20170031A2 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
NZ595235A (en) | Compositions and methods for increasing muscle growth | |
WO2013173496A3 (en) | Cd33 antibodies and use of same to treat cancer | |
EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
NZ611269A (en) | Neutralizing anti-ccl20 antibodies | |
MD20160130A2 (ro) | Anticorpi umanizaţi contra CEACAM1 | |
PH12016501366A1 (en) | Novel anti-baff antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |